潜在的生物标志物开发用于预测患有食道状细胞癌的患者在使用血清代谢药物优化化疗后的预后
Jie Yang1, Yunyun Zhu2, Yijian Zhou3,4
1Central Laboratory, Danyang People's Hospital of Jiangsu Province, Danyang, Jiangsu, 212300, P.R. China.
BMC cancer
|March 12, 2025
概括
同时化学放射治疗 (CCRT) 有效地治疗食道状细胞癌 (ESCC). 血清L-phenylalanine和lysine作为监测ESCC患者中CCRT疗效的生物标志物具有前景.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 癌症生物标志物 癌症生物标志物
背景情况:
- 食道状细胞癌 (ESCC) 的预后不好,治疗后预后标志物有限.
- 同时化疗放射治疗 (CCRT) 是ESCC的标准治疗方法,但监测其有效性需要更好的生物标志物.
研究的目的:
- 确定血清代谢生物标志物用于ESCC患者中CCRT的预后监测.
- 通过代谢概况来评估CCRT的治疗疗效.
主要方法:
- 血清样本从45名ESCC患者在CCRT前,CCRT期间和CCRT后一个月内收集.
- 非向的代谢分析确定了与CCRT治疗相关的差异性代谢物.
- 使用CT成像和RECIST 1.1标准评估治疗反应.
主要成果:
- 在ESCC患者中,CCRT显示出显著的治疗效果.
- 代谢分析显示,CCRT后氨基酸代谢和降低葡萄糖代谢的变化.
- 鉴定出L-phenylalanine和lysine是潜在的血清生物标志物,其AUC>0.661用于预测CCRT结果.
结论:
- CCRT是ESCC的有效治疗方法,导致代谢变化.
- 血清L-phenylalanine和lysine显示出作为ESCC中CCRT疗效的预测生物标志物的潜力.
相关概念视频
01:30Serum Laboratory Studies, Stool Test, Breath Test
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...